Aurobindo Pharm received Approval from USFDA to Manufacture & Market Divalproex

Corporate/Business Current Affairs 2011. Aurobindo Pharma Ltd received final approval from the US Food & Drug Administration to manufacture and market Divalproex Sodium Delayed- Release tablets

Created On: May 25, 2011 16:37 ISTModified On: May 25, 2011 16:37 IST

Aurobindo Pharma Ltd received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Delayed- Release tablets. The tablets are the generic equivalent of Abbott Laboratories' Depakote Delayed-Release Tablets and fall under the neurological therapeutic category.


The tablets are used for the treatment of the manic episodes associated with bipolar disorder. It is also for monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures and for prophylaxis of migraine headaches.


The product had a market size of approximately $144 million for the 12-month ended September 2010.

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

एग्जाम की तैयारी के लिए ऐप पर वीकली टेस्ट लें और दूसरों के साथ प्रतिस्पर्धा करें। डाउनलोड करें करेंट अफेयर्स ऐप

AndroidIOS
Comment ()

Related Stories

Post Comment

1 + 9 =
Post

Comments